RightFit
RecruitingPhase not listed

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years to 69 Years
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Biopsies

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment"
  • "Furthermore, results from retrospective analyses of two clinical trials (PCPT and REDUCE) and biopsy cohorts revealed Caucasian men with higher GRS are 1) more likely to have positive biopsy and 2) have higher number of positive biopsy cores."
  • "These findings suggest inherited risk assessment may have clinical utility in identifying men who have a higher likelihood of positive results from diagnostic prostate biopsy."
  • "Results from this trial will provide a critical piece of evidence for guideline committees to consider the adoption of inherited risk assessment in decision making for prostate biopsy."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well an inherited risk assessment predicts prostate cancer found by a biopsy. A biopsy takes small pieces of tissue to check for cancer, and an inherited risk assessment looks at risk passed down in families. The study is for adults ages 40 to 69 who are having a prostate biopsy and meet the listed requirements.

Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Having a prostate biopsy to check for prostate cancer.
  • Age 40 to 69.
  • White (Caucasian), African American, East Asian, or Latino.
  • PSA level between 2.5 and 10 ng/mL. PSA is a protein made by the prostate and measured in blood.

Who can't join

  • Have been diagnosed with prostate cancer before.
  • Have an ethnicity not listed above, including mixed ethnicity.
  • Have had any past PSA test result below 2.5 or above 10 ng/mL.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Consecutive patients undergoing prostate biopsy for detection of prostate cancer * Aged 40 to 69 years * Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos) * PSA between 2.5-10 ng/mL Exclusion Criteria: * Previous diagnosis of prostate cancer. * Ethnicity outside the inclusion criterion (including mixed ethnicity). * Any prior PSA test result outside the range of inclusion criterion.

Study sites (1)

IL